previously announced Series B, bringing the round’s overall to$25 million. The extension was led by SK Holdings, and included involvement from returning financiers including Heritas Capital and SEEDS Capital, the investment arm of Business Singapore
, a government firm that supports small-to medium-sized companies. This brings Hummingbird Bioscience’s overall raised so far to$65 million. Because the round was oversubscribed, the business says it extended its Series B. The new financing will be used to take treatments Hummingbird Bioscience is developing to clinical trials faster, and broaden research study and development for its early stage pipeline. Heritas Capital Management executive director and CEO Chik Wai Chiew stated in a press declaration that”Heritas Capital is pleased to continue our backing of the Hummingbird team since leading its Series A extended round. Even as the COVID-19 pandemic has resulted in a slow-down in investing, we are mindful that backing ingenious biotech companies, especially gamers such as Hummingbird, to develop remedies for dealing with patients’requirements remains our priority.”The business published information previously this year on two antibodies, both oncology treatments, and expects to make regulative submissions to begin Stage 1 research studies in the 2nd half of this year. Hummingbird Bioscience has workplaces in Singapore, Houston and South San Francisco and tactical collaborations with Cancer Research study United Kingdom and Amgen
. It was formerly granted an item development grant from the Cancer Avoidance and Research Study Institute of Texas. Article curated by RJ Shara from Source. RJ Shara is a Bay Area Radio Host (Radio Jockey) who talks about the startup ecosystem – entrepreneurs, investments, policies and more on her show The Silicon Dreams. The show streams on Radio Zindagi 1170AM on Mondays from 3.30 PM to 4 PM.